Clinical Research Directory
Browse clinical research sites, groups, and studies.
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
Sponsor: Houssam Farres, M.D.
Summary
Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.
Official title: A Phase I, Open Label Study of Allogeneic Adipose Derived Mesenchymal Stem Cells in Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2020-05-15
Completion Date
2027-06
Last Updated
2025-08-12
Healthy Volunteers
No
Conditions
Interventions
Adipose Derived Mesenchymal Stem Cells
The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution
Locations (1)
Mayo Clinic in Florida
Jacksonville, Florida, United States